Nutshell Therapeutics
AI-physics allosteric drug discovery for undruggable targets
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Nutshell Therapeutics (宇道生物) is a Shanghai-based clinical-stage biotech pioneering AI-powered allosteric drug discovery for proteins that are hard to drug with conventional approaches. Its proprietary AlloStar AI-physics hybrid platform supports a pipeline focused on oncology and expanding into other disease areas. Lead program NTS071, a p53 Y220C allosteric reactivator, is advancing in Phase I/II trials in the U.S. and China. Public company materials list offices in Shanghai and Hong Kong Science Park.
- Website
- allonutshell.com
- Stage
- series-b+
- Location
- Shanghai, China
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- AlloStar — AI-physics hybrid platform for allosteric drug discovery · Other